äœå€ïŒex vivoïŒã§éºäŒåçºçŸæäœããšããžã§ããã£ãã¯æäœãæœãããšã§ãT现èã®ç²åŒæå¶ããæç¶çãªå¹¹çŽ°èæ§ïŒT现èã®ç¶ç¶çãªå¢æ®èœåãèªå·±åçèœåãåºåœ¢ãããæé€ãããšãã§ã¯ã¿ãŒç¶æ ãžã®ååèœåïŒã®ç¶æãèªå°ããç¬èªæè¡ã«ãã£ãŠãåºåœ¢ããã«é©çšå¯èœãªé€å现èå ç«çæ³ã®éçºãè¡ã£ãŠãããã€ãªãã³ãã£ãŒ
ããŒã ããŒãžïŒhttps://lyell.com/
èæ¯ãšãã¯ãããžãŒïŒ
ã»å ç«ç³»ãå©çšããŠãããæ²»çããããå ç«çæ³ã¯ãå ç«ãã§ãã¯ãã€ã³ãé»å®³è¬ãäžéšã®æ£è ããã§èå¹ããããšããè¿å¹Žæ³šç®ã济ã³ãŠãããã ããããå ç«çæ³ã«ã¯å€ãããè¡ãããŠããæ²»çæ³ãšããŠãé€å现èå ç«çæ³ãããã ããæ£è ããã®T现èã¯æŽ»æ§åããŠãããšããæšæž¬ãããæ£è ããã®T现èãåãåºããäœå€ã§ããã«æŽ»æ§åã»å¢æ®ãããåŸãäœå ã«æ»ãå ç«åå¿ã®å¢åŒ·ãçãæ²»çæ³ã§ããããã®æ²»çæ³ã¯äžéšã®æ£è ããã§ã¯å¹æãèŠãããããå€ãã®æ£è ããã«ã¯æ²»çå¹æãèŠãããªãã£ããããã§ããã®æ²»çæ³ãçºå±ãããæ£è ããããåãåºããT现èã«å¯ŸããŠãäœå€ã«ãããŠCARïŒãã¡ã©æåå容äœïŒãéºäŒåå°å ¥ããäžã§äœå ã«æ»ããã®ãCAR-Tçæ³ã§ããããããç¹ã«è¡æ¶²ããã«ãããŠéåžžã«é«ãæ²»çå¹æãèŠãããããã«ã泚ç®ã济ã³ãŠããã
ã»ããããCAR-Tçæ³ã¯çŸåšã®ãšãããåºåœ¢ããã«å¯ŸããŠã®æ²»çå¹æã¯éå®çãšèšãããŠãããããã¯ãåºåœ¢ãããããè€éã§ãå ç«ç³»ãåé¿ããæçµçã«å ç«ç³»ãå æããããã®è€æ°ã®ã¡ã«ããºã ãé²åãããŠããããã ãšèããããŠããã
ã»ä»å玹ä»ããLyell Immunopharmaã¯ãåºåœ¢ããã«å¯Ÿããé€å现èå
ç«çæ³ ã®éçºãè¡ã£ãŠãããã€ãªãã³ãã£ãŒã§ãããLyell Immunopharmaã§ã¯ãT现èã®ç²åŒãšæç¶çãªå¹¹çŽ°èæ§ã®æ¬ åŠïŒT现èã®ç¶ç¶çãªå¢æ®èœåãèªå·±åçèœåãåºåœ¢ãããæé€ãããšãã§ã¯ã¿ãŒç¶æ
ãžã®ååèœåã®åªå€±ïŒããåºåœ¢ããã«å¯Ÿããé€å现èå
ç«çæ³ ã®æå¹æ§ãå¶éãã2ã€ã®å€§ããªéå£ã§ãããšèããæ°ããªæ²»çæ³ã®éçºãè¡ã£ãŠããããã®ç¬èªæè¡ãã©ãããã©ãŒã ã¯ãGen-Rããã³Epi-Rãšåä»ããããŠããã
ã»Gen-RïŒT现èãæ©èœäžå šç¶æ ã«ååããéã«çãã転åããã³ãšããžã§ããã£ãã¯ãªå€åã«èµ·å ããT现èã®æ¯æžãå æããããã®ãç¬èªã®çäœå€éºäŒååããã°ã©ã æè¡ã
Lyell Immunopharmaã®å
±ååµæ¥è
ã¯ãT现èã®ç²åŒããCAR -T现èãæå¹æ§ã瀺ããŠããè¡æ¶²ãããããåºåœ¢ããã§ããé »ç¹ã«èµ·ããããšãçºèŠãããGen-Rã®çºèŠã¯ãT现èãæ
¢æ§çãªæååºæ¿ãåããŠããå Žåã ãT现èãåžžã«ããªã³ãã®ç¶æ
ã§ãå
ç«æå¶çãªåºåœ¢è
«ç埮å°ç°å¢ïŒTMEïŒãšçµã¿åããããšãT现èã®ç²åŒãä¿é²ãããå¯èœæ§ãé«ããšããèªèãããGen-RãéçºãããGen-Rãšã¯ãåèšåºã®åºåœ¢ããã¢ãã«ã«ãããŠãT现èã®ç²åŒã«éèŠãªåœ¹å²ãæããããšãæããã«ãªã£ãŠããc-JUNãæé©ã«éå°çºçŸãããããšã§ãT现èã®ç²åŒãå
æããæè
«ç掻æ§ãå埩ãããæè¡ã§ããã
ã»Epi-RïŒèä¹ æ§ã®ãã幹现èæ§ãæã€æ°ããT现èéå£ãäœãåºããç¬èªã®çäœå€ãšããžã§ããã£ãã¯åããã°ã©ã æè¡ã
ããã§èšã幹现èæ§ãšã¯ãèªå·±åçãå¢æ®ãæç¶ãæè
«çå¹æãªã©ã®èœåãæã€T现èã®æ§è³ªã®ããšã§ããããŸã§ã«å
ç«çæ³ã®èšåºå¹æãšã®é¢é£æ§ãå ±åãããŠãããããããåºåœ¢ããã«å¯Ÿããé·æçãªå¹æãåŸãããã«ã¯ãæç¶æ§ã®ãã幹现èæ§ãå¿
èŠã§ãããšèããŠãããæç¶æ§ã®ãã幹现èæ§ãšã¯ããããæ¶æ»
ãããŸã§T现èããã®å¹¹çŽ°èæ§ãç¶æããèœåãããªãã¡ãããããã®æç¶çãªã·ã°ãã«ã«ãã£ãŠæŽ»æ§åãå¢æ®ãååãä¿é²ãããŠããã«ãé¢ããããT现èãèªå·±è€è£œããèœåãæããããšãæå³ããããŸãããããã®çŽ°èãå¢æ®ããããšã§ãå€æ©èœãªãšãã§ã¯ã¿ãŒçŽ°èã«ååããããååã®é²ãã§ããªãT现èã®éå£ãåå¢æ®ããããããåå«çŽ°èãçæãããããã«ãã£ãŠå¹¹çŽ°èæ§ãç¶æããããšèããŠãããEpi-Rã¯ããã®ãããªæ°žç¶çãªå¹¹çŽ°èã®ç¹æ§ãæã€T现èéå£ãæå³çãã€åçŸæ§ããçæããããã«èšèšãããŠãããããã«ãè
«ç浞最ãªã³ãç TILã«é¢é£ããŠãEpi-Rãé©çšããããšã§ãå¢æ®äžã«ããªã¯ããŒããªãã£ãå¢å ããå€æ§ãªè
«çããªã¢ã³ãã²ã³ãæšçãšããèœåãç¶æããT现èã®èª¿è£œç©ãçæãããã
ã»Lyell Immunopharmaã§ã¯ãGen-Rããã³Epi-Ræè¡ãã©ãããã©ãŒã ã掻çšããŠããã«ãã¢ããªãã£è£œåã®ãã€ãã©ã€ã³ãéçºããŠããã2022幎æ«ãŸã§ã«4ã€ã®INDç³è«ãäºå®ããŠããã
ãã€ãã©ã€ã³ïŒ
ã»LYL797
ROR1ãèªèããŠçµåãããŠãµã®ã®æR12æäœã«ç±æ¥ããäžæ¬éã®å¯å€ãã©ã°ã¡ã³ããšãç¬èªã«æé©åããäžç®æé·å åå容äœïŒEGFRoptïŒã®å®å šã¹ã€ãããæã€ãROR1ãæšçãšããéèå æäžã®èªå®¶ç§»æ€CAR -T现è補åãGen-RãšEpi-Ræè¡ãçšããŠããã
ROR1ã®çºçŸã¯äºåŸã®æªããšé¢é£ããŠããããŸããäžè¬çãªããæ£è ã®ããªãã®éšåãROR1ãçºçŸããŠãããROR1ã®çºçŸçãæãé«ã2ã€ã®é©å¿çã§ããããªãã«ãã¬ãã£ãä¹³ããïŒçŽ60ïŒ ïŒããã³éå°çŽ°èèºããïŒçŽ40ïŒ ïŒããã®äžäŸã§ããã
éçºäžã®é©å¿ç
ã»åèšåºç 究段éïŒ2022幎第1ååæINDç³è«äºå®ïŒ
ROR1éœæ§ã®éå°çŽ°èèºãããããªãã«ãã¬ãã£ãä¹³ããããã®ä»åºåœ¢ãã
ã»LYL845
Epi-Ræè¡ãçšããŠäœè£œãããèªå®¶ç§»æ€ã®è «ç浞最ãªã³ãç ïŒTILïŒã
çŸè¡ã®TILãçšããæ²»çæ³ã®æå¹æ§ã¯ãè «çåå¿æ§T现èã®è²§åŒ±ãªæ¿çž®ãå¢æ®ããT现èã®è³ªãšå¢æ®åã®äœããTILã®è£œé æã«ããªã¯ããŒããªãã£ãç¶æã§ããªãããšã«ãã£ãŠå¶éãããŠãããšèãããããLYL845ã¯ãç¬èªæè¡ã§ããEpi-Ræè¡ãåãå ¥ããŠèšèšãããŠãããT现èã®å䟡ãæè «ç掻æ§ãTILã®ããªã¯ããŒããªãã£ãåäžããã
éçºäžã®é©å¿ç
ã»åèšåºç 究段éïŒ2022幎åŸåINDç³è«äºå®ïŒ
ã¡ã©ããŒããåå®®é žéšãé é žéšãèµèãä¹³æ¿ãå€§è žãéå°çŽ°èèºãããªã©ã®åºåœ¢ãã
ã»NY-ESO-1ïŒGSK3377794ïŒ
NY-ESO-1æåãèªèããT现èå容äœãçºçŸããT现è補åãGen-Rãããã¯Epi-Ræè¡ãããã¯ãã®äž¡æ¹ãçšããã詳现äžæãGSKãšã®å ±åç 究éçºãè¡ã£ãŠããã
éçºäžã®é©å¿ç
ã»åèšåºç 究段éïŒ2022幎ååINDç³è«äºå®ïŒ
æ»èèè «ããã®ä»åºåœ¢ãã
æè¿ã®ãã¥ãŒã¹ïŒ
GSKãšãããæ£è ããã®ããã®çŽ°èæ²»çãåäžãããããã®æ°æè¡ã®éçºãç®çãšãã5幎éã®å ±åç 究ãç· çµãLyell Immunopharmaã®æè¡ãå¿çšããŠãè€æ°ã®ããçš®ã«çºçŸããNY-ESO-1æåãæšçãšãããGSK3377794ãã¯ãããšããGSKã®çŽ°èæ²»çãã€ãã©ã€ã³ã匷åã
ã³ã¡ã³ãïŒ
ã»Epi-Ræè¡ã«ã€ããŠã¯ã©ã®ãããªæè¡ãªã®ã詳现ã¯æããã«ãããŠããªãããšããžã§ããã£ã¯ã¹ãå¶åŸ¡ããæè¡ãšã®ããšã ããT现èã®å¹¹çŽ°èæ§ãç¶æãããšããããšã§ãæè¿æµè¡ã®çŽ°èã®è¥è¿ããèµ·ããæè¡ã ãããïŒ
ã»CAR-T现èçæ³ã®åºåœ¢ããå¿çšã¯éåžžã«ç«¶äºãæ¿ããããã®äŒç€Ÿã®ç¬èªæè¡ã®è©³çŽ°ã¯ããããªãããLYL797ã¯ROR1æåãçºçŸããªããã现èãããã°æµææ§ãåºãå¯èœæ§ãããããLYL845ã¯æ£è ããèªèº«ã®T现èãããæåãèªèã§ããªããšå¹æãäœãå¯èœæ§ããããåºåœ¢ããã®å€æ§æ§ã«å¯Ÿå¿ã§ãããã©ããã¯æªç¥æ°ã§ã¯ïŒ
ããŒã¯ãŒãïŒ
ã»çŽ°èæ²»çïŒCAR-Tçæ³ïŒ
ã»åºåœ¢ãã
ã»T现èç²åŒ
ã»ãšããžã§ããã£ã¯ã¹
å 責äºé ïŒ
æ£ç¢ºãªæ å ±æäŸãå¿ãããŠããŸãããæ¬å 容ã«åºã¥ããåŠäœãªãã¢ã¯ã·ã§ã³ã«å¯ŸããŠãã±ã³ã¯è²¬ä»»ããšããŸããããããããé¡ãããŸãã